Drug Discovery
insitro Virtual Human
Company-described AI-enabled discovery platform connecting human disease biology with therapeutic target development.
The Signal
insitro's AstraZeneca collaboration covers MASH and cardiomyopathies, with $40M upfront and up to approximately $1.46B in contingent milestones. This is a research partnership, not an equity financing round or evidence of clinical efficacy.
Company profileMore in Drug Discovery
Benchling
Cloud-based R&D platform designed for life sciences workflows, sample tracking, and collaboration.
View toolIsomorphic Labs
AI-first drug discovery company applying AlphaFold technology to design novel therapeutic molecules.
View toolSchrodinger
Computational platform for molecular modeling, physics-based simulations, and chemical property prediction.
View toolRecursion
Industrialized drug discovery platform combining biological wet-lab automation with machine learning analysis.
View toolRecursion OS
Maps biology at scale with automated labs and machine learning to find drug candidates.
View toolWhiteLab Genomics ALFRED
AI platform that designs viral and non-viral delivery vehicles and programmable payloads for genomic medicines.
View tool